TITLE:
Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis

CONDITION:
Diverticulitis, Colonic

INTERVENTION:
ertapenem

SUMMARY:

      The purpose of this study is to compare the efficacy (by assessing the clinical success of
      treatment) of intravenous antibiotic therapy with ertapenem in patients with acute attacks
      of sigmoid diverticulitis for 4 vs. 7 days.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  At least three of the following signs or symptoms of an acute attack of sigmoid
             diverticulitis must be present: *Fever (body temperature > 38C, sublingual),
             *Abdominal tenderness, *Leukocytosis (leukocytes > 10,000/l) and left shift of the
             differential blood count (>1% band forms), *Elevated CRP (> 20 mg/l)

          -  Evidence of sigmoid diverticulitis by contrast enema

          -  CT evidence of wall thickening in the sigmoid intestine

          -  Decision in favor of conservative therapy on the basis of the case history and
             diagnosis

        Exclusion Criteria:

          -  Contraindication for the use of the study medication or other beta-lactam
             antibiotics, e.g. patients with advanced renal impairment or patients requiring
             hemodialysis

          -  Antibiotic therapy in the two weeks prior to the start of the study

          -  Patients with an advanced incurable disease

          -  Patients with a hematologic/oncologic disease (leukemia, lymphoma)

          -  Patients on immunosuppressants

          -  Complications of sigmoid diverticulitis leading to an immediate indication for
             surgery

          -  Patients who have hypersensitivity to beta-lactam antibiotics

          -  Female patients who are pregnant or nursing or who could become pregnant during the
             study

          -  Participation in another clinical study or use of another study drug within the four
             weeks prior to enrollment in the study or use of another drug during the study

          -  Each patient can be enrolled only once in the study
      
